Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to compare the effect of integrase inhibitor-based vs. non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy on progression to diabetes among North American persons in HIV care

Next Previous
Trial Profile

A study to compare the effect of integrase inhibitor-based vs. non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy on progression to diabetes among North American persons in HIV care

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Efavirenz (Primary) ; Elvitegravir (Primary) ; Emtricitabine/tenofovir (Primary) ; HIV protease inhibitors (Primary) ; Integrase inhibitors (Primary) ; Lamivudine/abacavir (Primary) ; Non-nucleoside reverse transcriptase inhibitors (Primary) ; Raltegravir (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions
  • Acronyms NA-ACCORD

Most Recent Events

  • 16 Mar 2022 Data from this study used to examined whether low CD4/CD8 ratios predicted cancer among PWH in the USA and Canada published in the Journal of the National Cancer Institute
  • 16 Feb 2022 Results assessing associations between ADAP formulary openness and timely antiretroviral therapy (ART) initiation and viral suppression (VS) among PWH in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), presented at the 29th Conference on Retroviruses and Opportunistic Infections.
  • 16 Feb 2022 Data were used from NA-ACCORD to assess mental health disorders in people with Hiv and the effects on the Hiv Care Continuum presented at the 29th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top